Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| REINFORCE | Other Identifier | Allergan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| dexamethasone 700 ㎍ intravitreal implant | Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| dexamethasone 700 ㎍ intravitreal implant | Drug | Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices. |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye | Baseline, 12 Months | |
| Percentage of Patients with a BCVA Improvement of ≥15 Letters in the Study Eye | Baseline, 12 Months | |
| Average Change from Baseline in BCVA in the Study Eye | Baseline, 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Patients with an Increase from Baseline of ≥2 Lines in BCVA in the Study Eye | Baseline, 12 Months | |
| Percentage of Patients with an Increase from Baseline of ≥3 Lines in BCVA in the Study Eye | Baseline, 12 Months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with diabetic macular edema (DME) treated with (OZURDEX®) in clinical practice.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Retinal Consultants of Phoenix | Phoenix | Arizona | 85014 | United States | ||
| West Coast Retina |
Not provided
Not provided
Not provided
Not provided
|
|
| Percentage of Patients with BCVA of 20/40 or Better in the Study Eye | Baseline, 12 Months |
| Mean Number of Ozurdex Injections in the Study Eye | 12 Months |
| Mean Time Between Ozurdex Injections in the Study Eye | 12 Months |
| Change from Baseline in Central Retinal Subfield Thickness (CRT) in the Study Eye | Baseline, 12 Months |
| San Francisco |
| California |
| 94109 |
| United States |
| Orange Co Retina Medical Group | Santa Ana | California | 92705 | United States |
| Bay Area Retina Associates | Walnut Creek | California | 94598 | United States |
| Colorado Retina Associates | Denver | Colorado | 80230 | United States |
| Illinois Retina Associates | Harvey | Illinois | 60426 | United States |
| Raj Maturi, MD PC | Indianapolis | Indiana | 46290 | United States |
| John-Kenyon American Eye Institute | New Albany | Indiana | 47150 | United States |
| Associated Retina Consultants | Royal Oak | Michigan | 48073 | United States |
| Associated Retinal Consultants, PC | Traverse City | Michigan | 69686 | United States |
| Lifelong Vision Foundation | Chesterfield | Missouri | 63017 | United States |
| Eyesight Ophthalmic Services | Portsmouth | New Hampshire | 03801 | United States |
| New Jersey Retina | New Brunswick | New Jersey | 08901 | United States |
| Long Island Vitreoretinal Consultants - Long Island Retina - Hauppauge | Great Neck | New York | 11201 | United States |
| Mid Atlantic Retina | Philadelphia | Pennsylvania | 19109 | United States |
| Texas Retina Associates, Arlington | Arlington | Texas | 76012 | United States |
| Valley Retina Institute, P.A. | McAllen | Texas | 78503 | United States |
| Medical Center Ophthalmology Associates | San Antonio | Texas | 78240 | United States |
| ID | Term |
|---|---|
| D008269 | Macular Edema |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002123 | Calcium Dobesilate |
| ID | Term |
|---|---|
| D001557 | Benzenesulfonates |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D001190 | Arylsulfonates |
| D017739 | Arylsulfonic Acids |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |
Not provided
Not provided